Knightsbridge Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
Other funds holding REGN
Knightsbridge Asset Management's REGN Position: Q2 2026 in Review
Knightsbridge Asset Management reduced its Regeneron Pharmaceuticals (REGN) stake by 32% in Q2 2026, selling an estimated $191K and leaving 594 shares worth $370K. The position accounts for 0.05% of the portfolio, ranked #170.
Knightsbridge Asset Management first reported a position in REGN in Q3 2025 and has held it in 4 quarters since. The position peaked at $675K in Q1 2026. 1,335 funds tracked by Wall St. Rank hold REGN as of Q2 2026.
- Knightsbridge Asset Management held 594 shares of Regeneron Pharmaceuticals worth $370K as of Q2 2026.
- Knightsbridge Asset Management sold 280 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $191K.
- Regeneron Pharmaceuticals made up 0.05% of Knightsbridge Asset Management's portfolio in Q2 2026, its #170 holding.
- Knightsbridge Asset Management first reported a position in Regeneron Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
- Knightsbridge Asset Management's Regeneron Pharmaceuticals position peaked at $675K in Q1 2026.
- 1,335 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.
Based on Knightsbridge Asset Management's 13F filing for Q2 2026, filed 12 Aug 2026.